14:12 , May 16, 2017 |  BC Innovations  |  Distillery Therapeutics

Dermatology

INDICATION: Dermatosis Mouse studies suggest inhibiting SYK could help treat neutrophilic dermatosis. In a mouse model of the disease, myeloid-specific knockout of SYK delayed disease onset and lesion severity in the footpad compared with normal...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Leukemia & Lymphoma Society pipeline update

The Leukemia & Lymphoma Society launched the collaborative Phase IIa/IIb Beat AML trial, which will evaluate multiple candidates to treat first-line acute myelogenous leukemia (AML). The trial will enroll newly diagnosed AML patients ages >=60....
07:00 , Oct 24, 2016 |  BioCentury  |  Product Development

A new BEAT for AML

  With the first collaborative, multidrug trial in a blood cancer, The Leukemia & Lymphoma Society aims to dramatically alter the 40-year-old diagnosis and treatment paradigm in first-line acute myelogenous leukemia, and to create a...
07:00 , Oct 18, 2016 |  BC Extra  |  Top Story

LLS launches collaborative AML trial

On Tuesday, the Leukemia & Lymphoma Society launched the collaborative Phase IIa/IIb Beat AML trial, which will evaluate multiple candidates to treat first-line acute myelogenous leukemia. The trial will enroll newly diagnosed AML patients aged...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Clinical News

GS-9973: Additional Phase II data

Data from 41 evaluable chronic lymphocytic leukemia (CLL) patients who received twice-daily 800 mg oral GS-9973 for a median of 32 weeks in the single-arm, open-label, U.S. Phase II Study 102 showed that GS-9973 led...
07:00 , Mar 13, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug delivery

Approach Summary Licensing status Publication and contact information Drug delivery Drug-loaded, neutrophil-targeting nanoparticles to prevent inflammation-induced tissue damage Neutrophil-targeting nanoparticles could help prevent tissue damage involving vascular inflammation. In mice with vascular inflammation, bovine serum...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

GS-9973: Interim Phase II data

Interim data from 78 evaluable patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or non-Hodgkin's lymphoma (NHL) in the single-arm, open-label, U.S. Phase II Study 102 showed that twice-daily 800 mg oral GS-9973 was...
08:00 , Feb 16, 2012 |  BC Innovations  |  Targets & Mechanisms

SYKing inhibitors on retinoblastoma

Findings from St. Jude Children's Research Hospital and Washington University in St. Louis researchers show that spleen tyrosine kinase is epigenetically upregulated in retinoblastoma, suggesting that blocking its activity could help treat the disease. 1...